Imbruvica 140 mg contains ibrutinib, a targeted anticancer medicine classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It works by blocking BTK, a protein involved in the growth, activation, and survival of certain B cells, which are a type of white blood cell.
In some blood cancers, abnormal B cells depend on BTK signaling to survive and multiply. By inhibiting this protein, ibrutinib can interfere with cancer cell signaling and help control the progression of specific B-cell malignancies.
Imbruvica is prescribed for certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström’s macroglobulinemia (WM). It is also used for certain other conditions, depending on the patient’s diagnosis, age, previous treatment, and the applicable prescribing information.
Imbruvica 140 mg is available as a capsule in certain markets. The capsule strength does not represent the appropriate dose for every patient. Treatment must be prescribed and monitored by a qualified healthcare professional.
How Does Imbruvica 140 mg Capsule Work?
Imbruvica 140 mg contains ibrutinib, an oral targeted therapy used to treat specific blood cancers and certain immune-related complications following stem cell transplantation. It belongs to a class of medicines known as Bruton’s tyrosine kinase inhibitors.
BTK is an enzyme that helps regulate B-cell receptor signaling, which supports the growth and survival of certain B cells. In some blood cancers, this signaling pathway contributes to the multiplication and persistence of abnormal cells.
Ibrutinib blocks BTK activity, disrupting signals that cancerous B cells need to survive. This action can help control disease progression in patients whose conditions are suitable for treatment.
By interfering with these pathways, Imbruvica may reduce the activity of abnormal cells. However, it can also affect normal immune functions and blood cell counts, potentially causing side effects such as diarrhea, fatigue, bruising, and infections.
The medicine’s effectiveness depends on the diagnosed condition, individual response, and treatment regimen. Regular medical assessments are necessary to evaluate its benefits and identify complications.
Dosage of Imbruvica 140 mg Capsule :
Imbruvica 140 mg is an oral prescription medicine containing ibrutinib. It is used for specific conditions, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft-versus-host disease (cGVHD), according to approved indications.
The capsules are taken by mouth with a glass of water. They should be swallowed whole and must not be opened, broken, or chewed. Follow the instructions provided by the prescribing healthcare professional.
For adults with CLL/SLL or WM, the usual recommended dosage in the US prescribing information is 420 mg once daily. This may involve taking three 140 mg capsules, depending on the prescribed formulation and regimen. Dosage for cGVHD varies according to age, body surface area, and other clinical factors.
The appropriate dose may change because of side effects, liver function, or interactions with other medications. Certain medicines can significantly affect ibrutinib levels in the body.
Never change the dosage or stop treatment independently. An oncologist or other qualified specialist should determine the dose, treatment duration, and monitoring schedule based on the patient’s condition.
Benefits of Using Imbruvica 140 mg Capsule :
Imbruvica 140 mg is a targeted therapy that inhibits BTK activity. It is prescribed for specific blood cancers and certain cases of chronic graft-versus-host disease. Its potential benefits depend on the diagnosis, disease characteristics, and individual treatment response.
- Targeted treatment: Ibrutinib blocks a signaling protein involved in the growth and survival of certain abnormal B cells.
- Treatment for CLL/SLL: It can be used in eligible adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, either alone or with certain other medicines.
- Treatment for Waldenström’s macroglobulinemia: It may be prescribed alone or with rituximab for eligible adults with this type of blood cancer.
- Use in chronic graft-versus-host disease: It is approved for eligible adults and children aged one year and older whose condition has not responded adequately to one or more previous systemic treatments.
- Oral administration: The capsule formulation allows patients to take the medicine by mouth according to their prescribed treatment plan.
- Individualized treatment options: Healthcare professionals can adjust the regimen when clinically necessary to address adverse reactions or drug interactions.
Imbruvica may help control certain diseases, but it does not guarantee a cure or a particular outcome. Treatment benefits must be assessed against potential risks through regular medical follow-up.
Side Effects of Imbruvica 140 mg Capsule :
Treatment with Imbruvica may cause side effects ranging from mild symptoms to serious complications. The effects experienced can vary according to the underlying condition, dosage, other medications, and individual health.
Commonly reported side effects include:
- Diarrhea, nausea, and vomiting
- Fatigue and weakness
- Muscle, joint, or other musculoskeletal pain
- Bruising and an increased tendency to bleed
- Rash and other skin reactions
- Reduced blood cell counts, including neutropenia, anemia, and thrombocytopenia
- Fever and infections
Imbruvica can also cause serious adverse effects, including major bleeding, severe infections, abnormal heart rhythms, heart failure, high blood pressure, and liver injury. Rarely, serious complications may become life-threatening.
Seek urgent medical attention for significant or persistent bleeding, black stools, chest pain, fainting, severe shortness of breath, or symptoms of a serious infection. Contact a healthcare professional promptly if you develop a new or worsening symptom.
Regular monitoring may include blood counts, blood pressure, liver function, and assessment for bleeding, infection, or cardiac complications. Tell your doctor about all prescription medicines, over-the-counter products, and supplements you take because interactions may increase the risk of adverse effects.
Use Imbruvica only under appropriate medical supervision.
Conclusion :
Imbruvica 140 mg capsule contains ibrutinib, a targeted BTK inhibitor used to treat certain blood cancers and chronic graft-versus-host disease. Treatment suitability, dosage, and duration depend on the diagnosis and individual circumstances. Specialist supervision and regular monitoring are essential to evaluate treatment response and manage potential side effects.
Important Medical Warning :
Use Imbruvica 140 mg strictly according to your doctor’s prescription. Follow all instructions regarding dosage, administration, and treatment duration. Do not self-medicate, change your dose, or discontinue treatment without consulting your healthcare professional. Inform your doctor about existing medical conditions and other medicines you take. This medication requires appropriate medical supervision and regular monitoring for adverse effects and drug interactions.
Reviews
There are no reviews yet.